Evaluating Modes of Influenza Transmission 2b Baseline SAR
NCT ID: NCT07342556
Last Updated: 2026-01-15
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
NOT_YET_RECRUITING
Clinical Phase
NA
Total Enrollment
80 participants
Study Classification
INTERVENTIONAL
Study Start Date
2026-01-31
Study Completion Date
2026-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a research study to investigate how influenza transmits from person-to-person. Participation as a healthy "Recipient" in this study involves:
* Home semi-quarantine lasting about 14 days during which the participants must wear an N95 in class and take other precautions
* Daily assessments and clinic visits for 14 days
* Spending every weekday evening for about 14 days from around 6 - 10 pm, including a provided dinner, in a controlled environment. There may be additional sessions and different required participation times on weekends
* Exposure to people infected with influenza in the controlled environment
* Three blood draws, at the start, at the end of 14 days, and about a month after the end.
* A follow-up clinic visits one month after the end of home semi-quarantine
* A two-month follow-up phone call. This study may increase the participant's risk of catching influenza.
If the participants get infected during the study, the investigators may:
* Provide the participants with a prescription for antiviral medication or
* Refer the participants for medical care
* Ask the participants to become a Donor and expose other Recipients.
The participants will be compensated for their time and active participation in the study; however, they may not personally benefit from the study. While the participants may receive supportive care for an infection resulting from the study, this is not meant to replace their regular medical care. If the participants become very ill and need referral for medical care, they or their medical insurance will be billed.
If the participants are someone who recently became infected with influenza either through their daily activities or by participating in this study as a Recipient, they are invited to participate in this research study as a Donor and interact with a group of health participants in a controlled environment. Participation in this study as a Donor involves exposing Recipients for at least one and up to five days including:
* Attend exposure events in a controlled environment
* Weekday evenings from around 6-10 pm
* Additional day and evening events on weekends
* Events include a provided dinner
* Daily assessments and clinic visits for 1 to 5 days
* Provide exhaled breath samples for 30 to 60 minutes
* Three blood draws, at the start and end of exposure events, and about a month after the end
* A follow-up clinic visit one month after their last exposure event
* A two-month follow-up phone call
If the participants experience severe symptoms related to their influenza infection, we may:
* Provide the participants with a prescription for antiviral medication or
* Refer the participants for medical care
The participants will be compensated for their time and active participation in the study; however, they may not personally benefit from the study. While the participants may receive supportive care for their influenza infection, this is not meant to replace their regular medical care. If the participants become very ill and need referral for medical care, they or their medical insurance will be billed.
* Home semi-quarantine lasting about 14 days during which the participants must wear an N95 in class and take other precautions
* Daily assessments and clinic visits for 14 days
* Spending every weekday evening for about 14 days from around 6 - 10 pm, including a provided dinner, in a controlled environment. There may be additional sessions and different required participation times on weekends
* Exposure to people infected with influenza in the controlled environment
* Three blood draws, at the start, at the end of 14 days, and about a month after the end.
* A follow-up clinic visits one month after the end of home semi-quarantine
* A two-month follow-up phone call. This study may increase the participant's risk of catching influenza.
If the participants get infected during the study, the investigators may:
* Provide the participants with a prescription for antiviral medication or
* Refer the participants for medical care
* Ask the participants to become a Donor and expose other Recipients.
The participants will be compensated for their time and active participation in the study; however, they may not personally benefit from the study. While the participants may receive supportive care for an infection resulting from the study, this is not meant to replace their regular medical care. If the participants become very ill and need referral for medical care, they or their medical insurance will be billed.
If the participants are someone who recently became infected with influenza either through their daily activities or by participating in this study as a Recipient, they are invited to participate in this research study as a Donor and interact with a group of health participants in a controlled environment. Participation in this study as a Donor involves exposing Recipients for at least one and up to five days including:
* Attend exposure events in a controlled environment
* Weekday evenings from around 6-10 pm
* Additional day and evening events on weekends
* Events include a provided dinner
* Daily assessments and clinic visits for 1 to 5 days
* Provide exhaled breath samples for 30 to 60 minutes
* Three blood draws, at the start and end of exposure events, and about a month after the end
* A follow-up clinic visit one month after their last exposure event
* A two-month follow-up phone call
If the participants experience severe symptoms related to their influenza infection, we may:
* Provide the participants with a prescription for antiviral medication or
* Refer the participants for medical care
The participants will be compensated for their time and active participation in the study; however, they may not personally benefit from the study. While the participants may receive supportive care for their influenza infection, this is not meant to replace their regular medical care. If the participants become very ill and need referral for medical care, they or their medical insurance will be billed.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
DMID 21-0041; Influenza CVD 59000
NCT05666245
Influenza
COMPLETED
NA
Evaluating Modes of Influenza Transmission Observational Study of Community Acquired Influenza
NCT01769430
Influenza Virus Infection Transmission in Humans
COMPLETED
Evaluating Modes of Influenza Transmission
NCT01710111
Influenza, Human
COMPLETED
NA
Influenza Human Challenge Model
NCT05332899
Influenza
RECRUITING
PHASE1
Evaluating Modes of Influenza Transmission Between Humans
NCT01150149
Influenza
WITHDRAWN
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Influenza (Healthy Volunteers)
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Healthy people "Recipients" will be exposed to people who have recently become naturally infected with influenza virus in a controlled environment designed to maximize all major routes of respiratory viral infection transmission (touch contact, spray direct deposition (previously called droplet), and airborne-inhalation transmission.
Primary Study Purpose
BASIC_SCIENCE
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Exposure to Donors with naturally acquired influenza infection under controlled conditions
Recipients are exposed to Donors in a controlled environment while performing prescribed activities, including playing cards and other games, and periodically shaking hands with Donors and rubbing their own nose and eyes.
Group Type
OTHER
Exposure to Donors with naturally acquired influenza virus infection
Intervention Type
OTHER
Recipients are exposed to Donors in a controlled environment while performing prescribed activities, including playing cards and other games, and periodically shaking hands with Donors and rubbing their own nose and eyes.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Exposure to Donors with naturally acquired influenza virus infection
Recipients are exposed to Donors in a controlled environment while performing prescribed activities, including playing cards and other games, and periodically shaking hands with Donors and rubbing their own nose and eyes.
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Enrolled in the Recipient Registry (UMD IRB Protocol # 2303473, eligible age ≥18 and ≤49)
2. Provides written informed consent, can comply with the planned study procedures, is available for an up to \~14-day home semi-quarantine period, and can attend scheduled exposure events and scheduled follow-up visits.
3. Participants must be able to comprehend the study requirements, as evidenced by a score of 100% on the comprehension assessment (repeated tries permitted).
4. No significant change (for the worse) in general health history or in concomitant medication use, as compared from their responses collected during screening (Recipient Protocol).
5. Live in a private, single occupancy bedroom and agree to take precautions to avoid contracting a respiratory infection outside of the controlled exposure events through a home semi-quarantine prescribed by investigators.
6. Agree not to meet with other participants (Recipients or Donors) outside of the programmed exposure events during their participation in the home semi-quarantine.
1. Provides written informed consent, able to comply with the planned study procedures, available for between 1 and 5 days of multiple hour daily transmission experiments in a controlled environment research facility for the transmission trial and can attend the scheduled follow-up visits.
2. Comprehends the study requirements, as evidenced by a score of 100% on the comprehension assessment (repeated tries permitted).
3. Males and non-pregnant, non-breastfeeding females1 aged ≥18 and ≤59 years of age, at time of initial consent. Pregnancy and breastfeeding status to be determined by self-report.
4. Agrees to the collection of specimens for secondary research.
5. Evidence of onset of respiratory infection within the past 48 hours at time of entry into the Donor's initial exposure event, including one or more of the following:
1. Onset of influenza-like illness, as defined as fever (measured oral temperature of ≥100.2°F or self-reported fever in the absence of a measured temperature) AND cough or sore throat in the setting of local influenza activity.
2. Onset of less specific symptoms with a positive molecular test for influenza virus infection.
3. Laboratory-confirmed influenza infection (including rapid antigen test in the setting of known local influenza activity) with significant exposure to a laboratory confirmed influenza case (e.g., a roommate) within the last 4 days in the absence of symptoms.
2. Provides written informed consent, can comply with the planned study procedures, is available for an up to \~14-day home semi-quarantine period, and can attend scheduled exposure events and scheduled follow-up visits.
3. Participants must be able to comprehend the study requirements, as evidenced by a score of 100% on the comprehension assessment (repeated tries permitted).
4. No significant change (for the worse) in general health history or in concomitant medication use, as compared from their responses collected during screening (Recipient Protocol).
5. Live in a private, single occupancy bedroom and agree to take precautions to avoid contracting a respiratory infection outside of the controlled exposure events through a home semi-quarantine prescribed by investigators.
6. Agree not to meet with other participants (Recipients or Donors) outside of the programmed exposure events during their participation in the home semi-quarantine.
1. Provides written informed consent, able to comply with the planned study procedures, available for between 1 and 5 days of multiple hour daily transmission experiments in a controlled environment research facility for the transmission trial and can attend the scheduled follow-up visits.
2. Comprehends the study requirements, as evidenced by a score of 100% on the comprehension assessment (repeated tries permitted).
3. Males and non-pregnant, non-breastfeeding females1 aged ≥18 and ≤59 years of age, at time of initial consent. Pregnancy and breastfeeding status to be determined by self-report.
4. Agrees to the collection of specimens for secondary research.
5. Evidence of onset of respiratory infection within the past 48 hours at time of entry into the Donor's initial exposure event, including one or more of the following:
1. Onset of influenza-like illness, as defined as fever (measured oral temperature of ≥100.2°F or self-reported fever in the absence of a measured temperature) AND cough or sore throat in the setting of local influenza activity.
2. Onset of less specific symptoms with a positive molecular test for influenza virus infection.
3. Laboratory-confirmed influenza infection (including rapid antigen test in the setting of known local influenza activity) with significant exposure to a laboratory confirmed influenza case (e.g., a roommate) within the last 4 days in the absence of symptoms.
Exclusion Criteria
1. Female of childbearing potential who has a positive urine pregnancy test within 24 hours of enrollment in a Recipient Cohort or is breastfeeding or planning to become pregnant within 2 months after enrollment.
2. Presence of infection with influenza, SARS-CoV-2, or other respiratory pathogens detected via a multiplex nucleic acid amplification test (e.g., TaqMan Array Card assay) at entry to the transmission trial.
a. Volunteers with influenza infection may be eligible to enroll as Donors.
3. Within the past 72 hours, presence of influenza-like illness, as defined as fever of ≥100.2°F AND cough or sore throat, in the absence of an alternative cause.
4. Receipt of any blood products within the past 2 months.
5. Does not agree to provide permission for secondary research use of extra samples collected and stored specimens.
6. Habitual smoker of tobacco, marijuana, or e-cigarettes per self-report. (Habitual smokers are those who smoke or vape more than four cigarettes, other tobacco products, e-cigarettes or marijuana in a week for more than three months or use an inhaled nicotine or marijuana product more than 3 days a week on average. Edible or patch forms of tobacco or marijuana products do not constitute an exclusion.)
7. Self-reported or known history of alcohol or drug abuse in the past two years and/or illicit drug use within the last 30 days. (Prescribed stimulants for the treatment of ADHD and cannabinoids use do not constitute exclusionary criteria)
8. Has an ongoing symptomatic condition for which the individual has had or has ongoing medical investigations but has not yet received a diagnosis or treatment plan. (symptomatic condition means for example ongoing chronic fatigue without a diagnosis for symptom.)
9. Presence of self-reported or medically documented significant medical or psychiatric condition(s) Significant medical or psychiatric conditions include but are not limited to:
1. Respiratory disease (e.g., chronic obstructive pulmonary disease \[COPD\], asthma, cystic fibrosis) requiring daily medications\* currently or any treatment of respiratory disease exacerbations or hospitalizations for acute respiratory illnesses (e.g., asthma exacerbation) in the last 5 years. (\* Asthma medications: inhaled, oral, or intravenous (IV) corticosteroids, leukotriene modifiers, long and short acting beta agonists, theophylline, ipratropium, biologics.)
2. Significant cardiovascular disease (e.g., congestive heart failure, cardiomyopathy, ischemic heart disease) or history of myocarditis or pericarditis as an adult.
3. Neurological or neurodevelopmental conditions (e.g., epilepsy, stroke, seizures, encephalopathy, focal neurologic deficits, Guillain-Barré syndrome, encephalomyelitis or transverse myelitis).
4. Ongoing malignancy or recent diagnosis of malignancy, including leukemia; treated, non-melanoma skin cancers are permissible.
5. An autoimmune disease.
6. An immunodeficiency of any cause.
7. A blood disorder (e.g., sickle cell disease)
8. Endocrine disorders (e.g., diabetes)
9. Liver, kidney, metabolic disorders
10. BMI ≥40 kg/m2
11. Persistent post-viral syndromes with ongoing cardiovascular, respiratory, or neurologic conditions.
12. Any other condition or behavior that in the opinion of the PI would affect the ability to participate in the screening or future transmission studies.
10. Presence of immunosuppression or any medications that may be associated with impaired immune responsiveness. Including, but not limited to, corticosteroids exceeding 10 mg/day of prednisone equivalent, immunoglobulin, interferon, immunomodulators, cytotoxic drugs, or systemic corticosteroids or other similar or toxic drugs during the preceding 2-month period. Low dose topical and intranasal steroid preparations used for a discrete period are permitted.
11. Known allergy or intolerance to treatments for influenza and other respiratory infections (including but not limited to oseltamivir, baloxavir, acetaminophen/paracetamol).
12. History of a previous severe allergic reaction to medicines of any kind with generalized urticaria, angioedema, or anaphylaxis.
13. Participating in any other interventional clinical trial that has a scheduled intervention 30 days prior to the start or after the end of the home semi-quarantine.
1. Female of childbearing potential who is breastfeeding or has positive urine pregnancy test upon enrollment.
2. Presence of self-reported or medically documented significant medical or psychiatric condition(s) Significant medical or psychiatric conditions include but are not limited to:
1. Respiratory disease (e.g., chronic obstructive pulmonary disease \[COPD\], asthma, cystic fibrosis) requiring daily medications currently or any treatment of respiratory disease exacerbations or hospitalizations for acute respiratory illnesses (e.g., asthma exacerbation) in the last 5 years. Asthma medications: inhaled, oral, or intravenous (IV) corticosteroids, leukotriene modifiers, long and short acting beta agonists, theophylline, ipratropium, biologics.
2. Significant cardiovascular disease (e.g., congestive heart failure, cardiomyopathy, ischemic heart disease) or history of myocarditis or pericarditis as an adult.
3. Neurological or neurodevelopmental conditions (e.g., epilepsy, stroke, seizures, encephalopathy, focal neurologic deficits, Guillain-Barré syndrome, encephalomyelitis or transverse myelitis).
4. Ongoing malignancy or recent diagnosis of malignancy, including leukemia; treated, non-melanoma skin cancers are permissible.
5. An autoimmune disease.
6. An immunodeficiency of any cause.
7. A blood disorder (e.g., sickle cell disease)
8. Endocrine disorders (e.g., diabetes)
9. Liver, kidney, metabolic disorders
10. BMI ≥40 kg/m2
11. Persistent post-viral syndromes with ongoing cardiovascular, respiratory, or neurologic conditions.
12. Any other condition or behavior that in the opinion of the PI would affect the ability to participate in the transmission study over the next several days.
13. Meets criteria for escalation of care at the time of enrollment visit (will be referred for care).
3. Presence of immunosuppression or any medications that may be associated with impaired immune responsiveness Including, but not limited to, corticosteroids exceeding 10 mg/day of prednisone equivalent, immunoglobulin, interferon, immunomodulators, cytotoxic drugs, or systemic corticosteroids or other similar or toxic drugs during the preceding 2-month period. Low dose topical and intranasal steroid preparations used for a discrete period are permitted.
4. Ongoing symptomatic condition for which individual has had or has ongoing medical investigations but has not yet received a diagnosis or treatment plan.
e.g., ongoing and debilitating fatigue without a diagnosis for the symptom.
5. Self-reported or known history of alcohol or drug abuse within the past two years or illicit drug use within the last 30 days.
6. Is a habitual smoker of tobacco, marijuana, or e-cigarettes per self-report. Habitual smokers are those who smoke or vape more than four cigarettes, other tobacco products, e-cigarettes or marijuana in a week for more than three months or use an inhaled nicotine or marijuana product more than 3 days a week on average. Edible or patch forms of tobacco or marijuana products do not constitute an exclusion.
7. Known allergy or intolerance to treatments for influenza and other respiratory infections (including but not limited to acetaminophen/paracetamol).
8. History of a previous severe allergic reaction to medicines of any kind with generalized urticaria, angioedema, or anaphylaxis.
9. Presence of infection with SARS-CoV-2, as detected via a multiplex nucleic acid amplification test (e.g., Cepheid 4-Plex).
10. Participating in any other interventional clinical research study that has a scheduled intervention 30 days prior to or after the transmission trial.
11. Any condition, to include medical and psychiatric conditions, that in the opinion of the Investigator, might interfere with the safety of the participant or the study objectives.
2. Presence of infection with influenza, SARS-CoV-2, or other respiratory pathogens detected via a multiplex nucleic acid amplification test (e.g., TaqMan Array Card assay) at entry to the transmission trial.
a. Volunteers with influenza infection may be eligible to enroll as Donors.
3. Within the past 72 hours, presence of influenza-like illness, as defined as fever of ≥100.2°F AND cough or sore throat, in the absence of an alternative cause.
4. Receipt of any blood products within the past 2 months.
5. Does not agree to provide permission for secondary research use of extra samples collected and stored specimens.
6. Habitual smoker of tobacco, marijuana, or e-cigarettes per self-report. (Habitual smokers are those who smoke or vape more than four cigarettes, other tobacco products, e-cigarettes or marijuana in a week for more than three months or use an inhaled nicotine or marijuana product more than 3 days a week on average. Edible or patch forms of tobacco or marijuana products do not constitute an exclusion.)
7. Self-reported or known history of alcohol or drug abuse in the past two years and/or illicit drug use within the last 30 days. (Prescribed stimulants for the treatment of ADHD and cannabinoids use do not constitute exclusionary criteria)
8. Has an ongoing symptomatic condition for which the individual has had or has ongoing medical investigations but has not yet received a diagnosis or treatment plan. (symptomatic condition means for example ongoing chronic fatigue without a diagnosis for symptom.)
9. Presence of self-reported or medically documented significant medical or psychiatric condition(s) Significant medical or psychiatric conditions include but are not limited to:
1. Respiratory disease (e.g., chronic obstructive pulmonary disease \[COPD\], asthma, cystic fibrosis) requiring daily medications\* currently or any treatment of respiratory disease exacerbations or hospitalizations for acute respiratory illnesses (e.g., asthma exacerbation) in the last 5 years. (\* Asthma medications: inhaled, oral, or intravenous (IV) corticosteroids, leukotriene modifiers, long and short acting beta agonists, theophylline, ipratropium, biologics.)
2. Significant cardiovascular disease (e.g., congestive heart failure, cardiomyopathy, ischemic heart disease) or history of myocarditis or pericarditis as an adult.
3. Neurological or neurodevelopmental conditions (e.g., epilepsy, stroke, seizures, encephalopathy, focal neurologic deficits, Guillain-Barré syndrome, encephalomyelitis or transverse myelitis).
4. Ongoing malignancy or recent diagnosis of malignancy, including leukemia; treated, non-melanoma skin cancers are permissible.
5. An autoimmune disease.
6. An immunodeficiency of any cause.
7. A blood disorder (e.g., sickle cell disease)
8. Endocrine disorders (e.g., diabetes)
9. Liver, kidney, metabolic disorders
10. BMI ≥40 kg/m2
11. Persistent post-viral syndromes with ongoing cardiovascular, respiratory, or neurologic conditions.
12. Any other condition or behavior that in the opinion of the PI would affect the ability to participate in the screening or future transmission studies.
10. Presence of immunosuppression or any medications that may be associated with impaired immune responsiveness. Including, but not limited to, corticosteroids exceeding 10 mg/day of prednisone equivalent, immunoglobulin, interferon, immunomodulators, cytotoxic drugs, or systemic corticosteroids or other similar or toxic drugs during the preceding 2-month period. Low dose topical and intranasal steroid preparations used for a discrete period are permitted.
11. Known allergy or intolerance to treatments for influenza and other respiratory infections (including but not limited to oseltamivir, baloxavir, acetaminophen/paracetamol).
12. History of a previous severe allergic reaction to medicines of any kind with generalized urticaria, angioedema, or anaphylaxis.
13. Participating in any other interventional clinical trial that has a scheduled intervention 30 days prior to the start or after the end of the home semi-quarantine.
1. Female of childbearing potential who is breastfeeding or has positive urine pregnancy test upon enrollment.
2. Presence of self-reported or medically documented significant medical or psychiatric condition(s) Significant medical or psychiatric conditions include but are not limited to:
1. Respiratory disease (e.g., chronic obstructive pulmonary disease \[COPD\], asthma, cystic fibrosis) requiring daily medications currently or any treatment of respiratory disease exacerbations or hospitalizations for acute respiratory illnesses (e.g., asthma exacerbation) in the last 5 years. Asthma medications: inhaled, oral, or intravenous (IV) corticosteroids, leukotriene modifiers, long and short acting beta agonists, theophylline, ipratropium, biologics.
2. Significant cardiovascular disease (e.g., congestive heart failure, cardiomyopathy, ischemic heart disease) or history of myocarditis or pericarditis as an adult.
3. Neurological or neurodevelopmental conditions (e.g., epilepsy, stroke, seizures, encephalopathy, focal neurologic deficits, Guillain-Barré syndrome, encephalomyelitis or transverse myelitis).
4. Ongoing malignancy or recent diagnosis of malignancy, including leukemia; treated, non-melanoma skin cancers are permissible.
5. An autoimmune disease.
6. An immunodeficiency of any cause.
7. A blood disorder (e.g., sickle cell disease)
8. Endocrine disorders (e.g., diabetes)
9. Liver, kidney, metabolic disorders
10. BMI ≥40 kg/m2
11. Persistent post-viral syndromes with ongoing cardiovascular, respiratory, or neurologic conditions.
12. Any other condition or behavior that in the opinion of the PI would affect the ability to participate in the transmission study over the next several days.
13. Meets criteria for escalation of care at the time of enrollment visit (will be referred for care).
3. Presence of immunosuppression or any medications that may be associated with impaired immune responsiveness Including, but not limited to, corticosteroids exceeding 10 mg/day of prednisone equivalent, immunoglobulin, interferon, immunomodulators, cytotoxic drugs, or systemic corticosteroids or other similar or toxic drugs during the preceding 2-month period. Low dose topical and intranasal steroid preparations used for a discrete period are permitted.
4. Ongoing symptomatic condition for which individual has had or has ongoing medical investigations but has not yet received a diagnosis or treatment plan.
e.g., ongoing and debilitating fatigue without a diagnosis for the symptom.
5. Self-reported or known history of alcohol or drug abuse within the past two years or illicit drug use within the last 30 days.
6. Is a habitual smoker of tobacco, marijuana, or e-cigarettes per self-report. Habitual smokers are those who smoke or vape more than four cigarettes, other tobacco products, e-cigarettes or marijuana in a week for more than three months or use an inhaled nicotine or marijuana product more than 3 days a week on average. Edible or patch forms of tobacco or marijuana products do not constitute an exclusion.
7. Known allergy or intolerance to treatments for influenza and other respiratory infections (including but not limited to acetaminophen/paracetamol).
8. History of a previous severe allergic reaction to medicines of any kind with generalized urticaria, angioedema, or anaphylaxis.
9. Presence of infection with SARS-CoV-2, as detected via a multiplex nucleic acid amplification test (e.g., Cepheid 4-Plex).
10. Participating in any other interventional clinical research study that has a scheduled intervention 30 days prior to or after the transmission trial.
11. Any condition, to include medical and psychiatric conditions, that in the opinion of the Investigator, might interfere with the safety of the participant or the study objectives.
Minimum Eligible Age
18 Years
Maximum Eligible Age
49 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Sponsor Role
collaborator
University of Maryland, College Park
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Donald K. Milton
Distinguished University Professor
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Donald K Milton, MD, DrPH
Role: PRINCIPAL_INVESTIGATOR
University of Maryland School of Public Health
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Maryland
College Park, Maryland, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Nguyen-Van-Tam JS, Killingley B, Enstone J, Hewitt M, Pantelic J, Grantham ML, Bueno de Mesquita PJ, Lambkin-Williams R, Gilbert A, Mann A, Forni J, Noakes CJ, Levine MZ, Berman L, Lindstrom S, Cauchemez S, Bischoff W, Tellier R, Milton DK; EMIT Consortium. Minimal transmission in an influenza A (H3N2) human challenge-transmission model within a controlled exposure environment. PLoS Pathog. 2020 Jul 13;16(7):e1008704. doi: 10.1371/journal.ppat.1008704. eCollection 2020 Jul.
Reference Type
BACKGROUND
Lai J, Sobhani H, Coleman KK, Tai SS, Hong F, Sierra Maldonado I, Esparza Y, McPhaul KM, Zhu S, DeVoe DL, Ortiz JR, Chen S, Yellin T, Carreno JM, Krammer F, Cowling BJ, Gordon A, Chen WH, Srebric J, Milton DK; EMIT-2 Study Team. Evaluating modes of influenza transmission (EMIT-2): Insights from lack of transmission in a controlled transmission trial with naturally infected donors. PLoS Pathog. 2026 Jan 7;22(1):e1013153. doi: 10.1371/journal.ppat.1013153. Online ahead of print.
Reference Type
BACKGROUND
Related Links
Access external resources that provide additional context or updates about the study.
https://sites.google.com/umd.edu/phablabumd/emit-2b
A link for information about volunteering as a healthy participant
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2313702-Baseline-SAR
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Influenza A H3N2 Human Challenge Study in Healthy Adult Volunteers
NCT02594189
COMPLETED
PHASE1
Dose, Safety, and Pathogenicity of a New Influenza A H3N2 Challenge Strain
NCT06613737
COMPLETED
NA
Characterisation of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model
NCT02525055
COMPLETED
NA
Dose, Safety, and Pathogenicity of a New Influenza B Strain
NCT06254820
RECRUITING
PHASE2
Safety and Immunogenicity of Live Influenza A Vaccine for Avian Influenza H7N7
NCT00922259
COMPLETED
PHASE1
Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A
NCT02572817
COMPLETED
PHASE3
A Study of Exclusion Criteria in a University Population
NCT01472536
COMPLETED
NA
Trial to Assess the Shedding,Immunogenicity, and Safety of FluMist Administered to Healthy Individuals 5-49 Years of Age
NCT00192140
COMPLETED
PHASE4
Influenza Immunity in Children
NCT02559505
COMPLETED
NA
A Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy Adults
NCT02623322
COMPLETED
PHASE2
Safety and Immune Response to Recombinant Live-Attenuated Influenza H2N2 Virus Vaccine
NCT00722774
COMPLETED
PHASE1
Dose, Safety, and Pathogenicity of a New Influenza H1N1 Challenge Strain
NCT05572450
COMPLETED
NA
Does Seasonal Influenza Vaccination Affect the Incidence of pH1N1 Influenza?
NCT01001325
COMPLETED
PHASE3
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
NCT01052480
COMPLETED
PHASE2
Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects
NCT00845429
COMPLETED
PHASE2
Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2, Clade 3C3a) Influenza Strain
NCT04978454
COMPLETED
PHASE1
Transmission of Influenza Virus From Asymptomatic Healthcare Workers and Inpatients in the Acute Care Hospital Setting
NCT02478905
COMPLETED
Evaluation of Influenza-Specific Immune Responses in Children and Adults During the 2010-2011 Influenza Season in the U.S.
NCT01262079
COMPLETED
B-cell Immunity to Influenza (SLVP017)- Year 1, 2009
NCT02133781
COMPLETED
PHASE4
Establishing a Controlled Human Infection Model for Influenza H3N2 as a Foundation for Pandemic Preparedness
NCT07305207
NOT_YET_RECRUITING
PHASE1
Safety and Immunogenicity of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant
NCT02957656
COMPLETED
PHASE1
Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine.
NCT00192309
COMPLETED
PHASE2
Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults
NCT00125944
COMPLETED
PHASE3
H7N9 Boost in Healthy Adults
NCT02586792
COMPLETED
PHASE2
A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.
NCT00545532
COMPLETED
PHASE3